The Question That Drives a $200 Billion Market Every time a pharmacist hands a patient a generic substitute for a […]

How the Hybrid Regulatory Strategy Cuts Risk, Compresses Timelines, and Unlocks Pipeline Value for Pharmaceutical Executives Why Most Drug Developers

A forward-looking analysis of the Inflation Reduction Act’s structural impact on U.S. pharmaceutical economics The Price Is Wrong: What the

Pharmaceutical companies spend decades constructing legal fortresses around their best-selling drugs. They file dozens of secondary patents on minor formulation

Introduction: Licensing as the Lifeblood of Biopharmaceutical Innovation In biopharmaceutical innovation the drug patent licensing agreement stands as the central,

A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent.

In the multi-trillion-dollar pharmaceutical industry, there’s an attic. It’s filled not with dust and forgotten relics, but with something far

Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred

When Pfizer launched atorvastatin (Lipitor) in 1997, it did not simply sell a cholesterol drug. It built, over the next